Pharmacologic targeting of this axis mainly relies on anti-CSF1 or anti-CSF1R agents as well as on CSF1R tyrosine kinase inhibitors (TKIs) and has shown anti-tumor activity in several pre-clinical models [33,34]. This evidence concerns the gene CSF1R and neoplasm.